Observational studyUrology practice2025
Use of Doublet or Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer Across Community-Based Urology Settings in the United States.
Observational study in Urology practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionThis study examines patient clinical profiles and real-world utilization patterns of darolutamide doublet (DT; androgen deprivation therapy alone) and triplet therapy (TT; androgen deprivation therapy and docetaxel) for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
methodsThis was a retrospective, observational study using the Precision Point Specialty Analytics (Specialty Networks) patient population health management platform to identify adult men with mHSPC who received darolutamide DT or TT between July 1, 2019, and March 31, 2023.
resultsOf 420 patients, 249 received DT and 171 received TT. Most patients included in the analysis were non-Hispanic White (DT: 67.1%; TT: 63.2%) and had Medicare insurance (DT: 77.5%; TT: 54.4%). Comorbid conditions were common, with hypertension (32.4%) and diabetes (15.0%) being the most prevalent. The mean PSA value on the index date was 20.9 ng/mL (SD 87.2 ng/mL) in the DT cohort and 66.4 ng/mL (SD 286.4 ng/mL) in the TT cohort. Most patients presented with high-grade cancer at diagnosis, with 50.6% of patients in the DT cohort and 74.2% of patients in the TT cohort having a high (≥8) Gleason score at diagnosis. The median duration of darolutamide treatment was 48 weeks in the DT cohort and 46 weeks in the TT cohort.
conclusionsThis study demonstrated that darolutamide DT and TT are used ubiquitously across community urology practices in the United States for the treatment of mHSPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.